Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. The spoils of war and the long-term spoiling of health conditions of entire nations

    Publikation: Bidrag til tidsskriftLederpeer review

Vis graf over relationer

BACKGROUND AND AIMS: We tested the hypotheses (i) that elevated lipoprotein(a) is causally associated with both mitral and aortic valve calcification and disease, and (ii) that aortic valve calcification mediates the effect of elevated lipoprotein(a) on aortic valve stenosis.

METHODS: From the Copenhagen General Population study, we included 12,006 individuals who underwent cardiac computed tomography to measure mitral and aortic valve calcification and 85,884 to examine risk of heart valve disease. Participants had information on plasma lipoprotein(a) and genetic instruments associated with plasma lipoprotein(a) to investigate potential causality.

RESULTS: At age 70-79 years, 29% and 54% had mitral and aortic valve calcification, respectively. For 10-fold higher lipoprotein(a) levels, multifactorially adjusted odds ratios for mitral and aortic valve calcification were 1.26 (95% confidence interval: 1.13-1.41) and 1.62 (1.48-1.77). For mitral and aortic valve stenosis, corresponding hazard ratios were 0.93 (95%CI:0.40-2.15, 19 events) and 1.54 (1.38-1.71, 1158 events), respectively. For ≤23 versus ≥36 kringle IV type 2 number of repeats, the age and sex adjusted odds ratios for mitral and aortic valve calcification were 1.53 (1.18-1.99) and 2.23 (1.81-2.76). For carriers versus non-carriers of LPA rs10455872, odds ratios for mitral and aortic valve calcification were 1.33 (1.13-1.57) and 1.86 (1.64-2.13). For aortic valve stenosis, 31% (95%CI:16%-76%) of the effect of lipoprotein(a) was mediated through calcification.

CONCLUSIONS: Elevated lipoprotein(a) was genetically and observationally associated with mitral and aortic valve calcification and aortic valve stenosis. Aortic valve calcification mediated 31% of the effect of elevated lipoprotein(a) on aortic valve stenosis.

OriginalsprogEngelsk
TidsskriftAtherosclerosis
Vol/bind349
Sider (fra-til)166-174
Antal sider9
ISSN0021-9150
DOI
StatusUdgivet - maj 2022

Bibliografisk note

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

ID: 72640030